BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding Board meeting held on August 05, 2025.
BALAXI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.3 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2025. On a standalone basis, revenue from operations fell to Rs 1,670.82 lakhs from Rs 1,902.58 lakhs in Q1 FY25, a drop of about 12%, while net profit plunged to Rs 19.49 lakhs from Rs 137.63 lakhs. On a consolidated basis, revenue rose modestly to Rs 7,074.21 lakhs (up ~8% YoY), but net profit collapsed to Rs 29.01 lakhs from Rs 648.04 lakhs, a roughly 95% fall, driven by higher employee and administrative costs. The board was also updated on the first pharmaceutical formulation plant at Jadcherla, Hyderabad, where equipment qualifications are complete, the manufacturing test licence has been obtained, and stability batch production is expected to begin in early September 2025. Additionally, the company's Dubai subsidiary acquired 100% stake in Balaxi Healthcare Nicaragua during the quarter. Statutory auditors P. Murali & Co. issued an unqualified limited review report.
Sharp YoY decline in profitability on both standalone and consolidated fronts, despite stable-to-growing revenue, signals significant cost pressure and weak Q1 earnings, which may weigh on the stock. Progress at the new formulation plant and the Nicaragua acquisition are positive forward-looking steps, but near-term earnings momentum is weak.